Research programme: intraocular therapeutics - Imprimis Pharmaceuticals

Drug Profile

Research programme: intraocular therapeutics - Imprimis Pharmaceuticals

Alternative Names: Epinephrine/lidocaine; Go Dropless; IPI-140; Lidocaine/epinephrine; Lidocaine/phenylephrine combination; Lyophilized epinephrine combination; Moxifloxacin/triamcinolone; Shugarcaine combination; Triamcinolone/moxifloxacin; Triamcinolone/vancomycin; TriMox; TriMox/vancomycin; TriMoxi; TriMoxi/vancomycin; Vancomycin/moxifloxacin/triamcinolone

Latest Information Update: 18 Nov 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eye Care Northwest; Novel Drug Solutions
  • Developer Imprimis Pharmaceuticals
  • Class Acetanilides; Azabicyclo compounds; Catecholamines; Cyclopropanes; Ethanolamines; Fluorinated steroids; Fluoroquinolones; Glucocorticoids; Glycopeptides; Piperidines; Pregnadienes; Pyrrolidines; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Postoperative infections; Postoperative inflammation

Most Recent Events

  • 18 Nov 2014 Discontinued - Preclinical for Postoperative infections (Prevention) and Postoperative inflammation (Prevention) in USA (Intraocular)
  • 18 Nov 2014 Discontinued - Preclinical for Postoperative inflammation (Prevention) in USA (Intraocular)
  • 28 Aug 2013 Preclinical trials in Postoperative infections in USA (Intraocular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top